Hantz Financial Services Inc. Sells 22,862 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Hantz Financial Services Inc. trimmed its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 14.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 138,910 shares of the biopharmaceutical company's stock after selling 22,862 shares during the period. Hantz Financial Services Inc. owned approximately 0.11% of Halozyme Therapeutics worth $6,641,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of HALO. SWP Financial LLC acquired a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at $366,000. Marshall Financial Group LLC bought a new stake in Halozyme Therapeutics during the 4th quarter worth about $1,530,000. First Citizens Bank & Trust Co. grew its position in shares of Halozyme Therapeutics by 16.9% during the 4th quarter. First Citizens Bank & Trust Co. now owns 4,704 shares of the biopharmaceutical company's stock worth $225,000 after buying an additional 681 shares during the period. Janney Montgomery Scott LLC lifted its holdings in Halozyme Therapeutics by 698.8% in the fourth quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company's stock valued at $13,756,000 after buying an additional 251,711 shares during the period. Finally, Sugar Maple Asset Management LLC acquired a new position in shares of Halozyme Therapeutics in the 4th quarter valued at $373,000. Institutional investors and hedge funds own 97.79% of the company's stock.

Halozyme Therapeutics Trading Up 1.7 %

HALO stock traded up $0.98 during midday trading on Thursday, hitting $56.81. The stock had a trading volume of 365,237 shares, compared to its average volume of 1,363,781. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. The business has a fifty day moving average price of $50.28 and a two-hundred day moving average price of $54.28. Halozyme Therapeutics, Inc. has a 1-year low of $33.15 and a 1-year high of $65.53. The firm has a market cap of $7.23 billion, a P/E ratio of 18.81, a price-to-earnings-growth ratio of 0.42 and a beta of 1.24.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Wells Fargo & Company lowered their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. Cowen reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Piper Sandler increased their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a report on Friday, January 10th. JMP Securities boosted their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a "market outperform" rating in a research report on Friday, November 1st. Finally, HC Wainwright raised their price target on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a "buy" rating in a research report on Friday, January 10th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $60.89.

Insider Activity at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 10,000 shares of the business's stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the completion of the sale, the director now owns 43,611 shares in the company, valued at $2,180,986.11. The trade was a 18.65 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 2.40% of the stock is owned by corporate insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.